Date: 2015-06-11
Type of information: Nomination
Compound:
Company: Seres Therapeutics (USA - MA)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 11, 2015, Seres Therapeutics, a leading microbiome therapeutics platformcompany developing a novel class of Ecobiotic® drugs designed to treat disease by restoring the function of a dysbiotic microbiome, announced that Dennis Ausiello, M.D., has been elected to the company’s board of directors. Dr. Ausiello, the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School and Chair of Medicine, Emeritus at Massachusetts General Hospital (MGH), is an internationally acclaimed clinician who brings a wealth of academic and clinical experience in medicine to Seres.
Dr. Ausiello is a nationally recognized leader in academic medicine and was Chief of Medicine at the MGH from 1996 until 2013. He currently serves as Director of the Center for Assessment Technology and Continuous Health (CATCH), a collaboration between MGH and the Massachusetts Institute of Technology that is committed to the discovery and application of new ways to quantitatively measure the human condition (phenotypes) in health and disease. He has made a substantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction, and has published numerous articles, book chapters and textbooks. Previously, Dr. Ausiello served as Chief of the MGH Renal Unit, overseeing its development into one of the most sought-after research and training programs in the world. He also serves on the board of directors of Pfizer.
Financial terms:
Latest news:
